文献速递皮肤肿瘤

维莫非尼促进BRAF抑制剂耐药BRAFV600E/NRASQ61K黑色素瘤的上皮间质转化基因表达并增强肿瘤生长转移

Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.
PubMed 文献 · J Invest Dermatol · 2021-10-21

本研究比较仅NRAS突变状态不同的同源黑色素瘤细胞(BRAFi敏感A375-BRAFV600E/NRASQ61与BRAFi耐药A375-BRAFV600E/NRASQ61K),发现维莫非尼选择性上调耐药细胞的EMT基因表达,促进体外侵袭和体内肺转移,而敏感细胞则被抑制。

要点

  • NRASQ61K状态使黑色素瘤细胞对BRAFi耐药并上调EMT相关基因网络。
  • 维莫非尼进一步加剧BRAFV600E/NRASQ61K细胞的EMT基因表达和侵袭表型。
  • SCID小鼠模型中维莫非尼增加NRASQ61K细胞的肺肿瘤负荷。

核心结论

  • 维莫非尼在BRAFi耐药的BRAFV600E/NRASQ61K黑色素瘤中促进EMT基因表达、增殖、侵袭和转移。

研究设计与样本

  • 研究采用同源黑色素瘤细胞系(A375-BRAFV600E/NRASQ61与A375-BRAFV600E/NRASQ61K)进行表型和转录组分析,并在SCID小鼠生物发光黑色素瘤转移模型中验证。

主要发现

  • NanoString nCounter转录组分析显示NRASQ61K状态上调EMT及EMT至转移相关基因网络。
  • EMT聚焦RT2 Profiler qPCR阵列显示维莫非尼进一步上调BRAFV600E/NRASQ61K细胞的EMT基因,而在BRAFV600E/NRASQ61细胞中下调EMT驱动基因。
  • 维莫非尼增强BRAFV600E/NRASQ61K细胞的增殖和侵袭,并激活磷酸化蛋白激酶B(Ser473),而在BRAFV600E/NRASQ61细胞中下调磷酸化蛋白激酶B和磷酸化细胞外信号调节激酶1/2。
  • SCID小鼠生物发光转移模型中,维莫非尼增加BRAFV600E/NRASQ61K细胞的肺肿瘤负荷,同时阻断BRAFV600E/NRASQ61细胞的转移。

临床怎么用

  • 对于NRAS驱动的BRAFi耐药黑色素瘤患者,接受BRAFi治疗可能 paradoxically 促进肿瘤生长和转移,需谨慎评估。

局限性

  • 研究为临床前体外和小鼠模型数据,尚未在患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRAF inhibitor (BRAFi) resistance compromises long-term survivorship of patients with malignant melanoma, and mutant NRAS is a major mediator of BRAFi resistance. In this study, employing phenotypic and transcriptomic analysis of isogenic melanoma cells that differ only by NRAS mutational status (BRAFi-sensitive A375-BRAFV600E/NRASQ61 vs. BRAFi-resistant A375-BRAFV600E/NRASQ61K), we show that BRAFi (vemurafenib) treatment selectively targets BRAFV600E/NRASQ61K cells upregulating epithelial-to-mesenchymal transition (EMT) gene expression, paradoxically promoting invasiveness and metastasis in vitro and in vivo. First, NanoString nCounter transcriptomic analysis identified the upregulation of specific gene expression networks (EMT and EMT to metastasis) as a function of NRASQ61K status. Strikingly, BRAFi treatment further exacerbated the upregulation of genes promoting EMT in BRAFV600E/NRASQ61K cells (with opposing downregulation of EMT-driver genes in the BRAFV600E/NRASQ61 genotype) as detected by EMT-focused RT2 Profiler qPCR array analysis. In BRAFV600E/NRASQ61K cells, BRAFi treatment enhanced proliferation and invasiveness, together with activation of phosphorylated protein kinase B (Ser473), with opposing phenotypic effects observable in BRAFV600E/NRASQ61 cells displaying downregulation of phosphorylated protein kinase B and phosphorylated extracellular signal-regulated kinase 1/2. In a SCID mouse bioluminescent melanoma metastasis model, BRAFi treatment enhanced lung tumor burden imposed by BRAFV600E/NRASQ61K cells while blocking BRAFV600E/NRASQ61 metastasis. These preclinical data document the BRAFi-driven enhancement of tumorigenesis and metastasis in BRAFi-resistant human BRAFV600E/NRASQ61K melanoma, a finding with potential clinical implications for patients with NRAS-driven BRAFi-resistant tumors receiving BRAFi treatment.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Jandova J, Wondrak GT. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model. J Invest Dermatol. 2021. PMID: 34687745. doi:10.1016/j.jid.2021.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。